Citation: | YUAN Ni, TIAN Tingting, ZHANG Haijun, WANG Yong. Major routes for orphan drugs to be incorporated into the reimbursement system of UK and the enlightenment to China[J]. Journal of China Pharmaceutical University, 2019, 50(1): 113-119. DOI: 10.11665/j.issn.1000-5048.20190116 |
[1] |
Gong SW.Study of management strategies of improving access to orphan drugs in china(促进我国罕见病患者药品可及性的管理策略研究)[D].Wuhan:Huazhong University of Science and Technology,2008.
|
[2] |
Sui BY,Qi XR.Experience from translation mechanisms in the NICE health technology assessment to NHS decision making[J].Chin J Health Policy(中国卫生政策研究),2015,8(7):74-78.
|
[3] |
National Institute for Health and Care Excellence.Guide to the processes of technology appraisal2014[R].London:NICE,2014.
|
[4] |
National Institute for Health and Care Excellence.Summary of decisions[EB/OL].[2018-03-19] .https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice technology-appraisal-guidance/summary-of-decisions.
|
[5] |
National Institute for Health and Care Excellence.Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease[R].London:NICE,2017.
|
[6] |
National Institute for Health and Care Excellence.Summary of decisions[EB/OL].[2018-05-17] .https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/summary-of-decisions.
|
[7] |
National Institute for Health and Care Excellence.Guide to the processes of technology appraisal 2014[R].London:NICE,2014.
|
[8] |
National Institute for Health and Care Excellence.Eltrombopag for treating chronic immune(idiopathic)thrombocytopenic purpura[R].London:NICE,2013.
|
[9] |
National Institute for Health and Care Excellence.Interim process and methods of the highly specialized technologies programme[R].London:NICE,2017.
|
[10] |
National Health Service.Specialized services[EB/OL].[2018-05-18] .https://www.england.nhs.uk/commissioning/spec-services/.
|
[11] |
NHS England.Implementation plan for the uk strategy for rare diseases[R].England:NHS England,2018.
|
[12] |
NHS England Cancer Drugs Fund Team.Appraisal and funding of cancer drugs from July 2016(including the new Cancer Drugs Fund)- A new deal for patients,taxpayers and industry[R].England:NHS England,2016.
|
[13] |
NHS England Cancer Drugs Fund Team.National cancer drugs fund list[R].England:NHS England,2016.
|
[14] |
National Institute for Health and Care Excellence.Consultation comments on the draft remit and draft scope for the technology appraisal of cabozantinib for previously treated advanced renal cell carcinoma[R].England:NICE.
|
[15] |
Specialized Commissioning Team.Standard operating procedures:individual funding requests[R].England:NHS England,2017.
|
[16] |
NHS England.Methods:Commissioning through Evaluation[R].England:NHS England,2017.
|
[17] |
National Health Service.Commissioning through evaluation[EB/OL].[2018-05-20] .https://www.england.nhs.uk/commissioning/spec-services/npc-crg/comm-eval/.
|
[1] | YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. Journal of China Pharmaceutical University, 2024, 55(5): 590-602. DOI: 10.11665/j.issn.1000-5048.2024052202 |
[2] | LUO Xuelian, WU Chengsheng, ZHA Cheng, LIU Sheng. Research progress and prospects of implantable drug delivery systems for postoperative tumor therapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 538-547. DOI: 10.11665/j.issn.1000-5048.2024040901 |
[3] | WANG Shihao, LIU Lifeng, DING Yang, LI Suxin. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 522-529. DOI: 10.11665/j.issn.1000-5048.2024011902 |
[4] | YU Jiayu, LIN Zezhi, CAO Wei, ZHANG Jianjun, WEI Yuanfeng, GAO Yuan, QIAN Shuai. Research progress of bio-metal organic frameworks in drug delivery system[J]. Journal of China Pharmaceutical University, 2023, 54(1): 23-33. DOI: 10.11665/j.issn.1000-5048.20221111003 |
[5] | ZHOU Yeshu, WANG Yanmei, ZHANG Beiyuan, WU Shuaicong, YANG Lei, YIN Lifang. Research progress of inorganic nanomaterials in drug delivery system[J]. Journal of China Pharmaceutical University, 2020, 51(4): 394-405. DOI: 10.11665/j.issn.1000-5048.20200403 |
[6] | LI Haoxian, LIN Huaqing, CHEN Jingwen, WANG Liyuan. Research progress of carbon nanomaterials in cancer drug delivery[J]. Journal of China Pharmaceutical University, 2019, 50(1): 100-106. DOI: 10.11665/j.issn.1000-5048.20190114 |
[7] | FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302 |
[8] | CHEN Xing, KANG Yang, WU Jun. Advances in biodegradable functional polymers based protein drug delivery system[J]. Journal of China Pharmaceutical University, 2017, 48(2): 142-149. DOI: 10.11665/j.issn.1000-5048.20170203 |
[9] | WANG Yazhe, ZHOU Jianping, DING Yang, WANG Wei. Advances in research of biomimetic drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(3): 267-273. DOI: 10.11665/j.issn.1000-5048.20140303 |
[10] | TANG Yue, KE Xue. Advances of mesoporous silica nanoparticles as drug delivery system[J]. Journal of China Pharmaceutical University, 2012, 43(6): 567-572. |